Evonik divests US betaine business based in Hopewell, Virginia, including staff and part of the site, to Kensing, a specialty chemicals company; divestment supports Evonik's strategy to become System Solutions provider for personal care, cleaning markets

Sample article from our Tissue & Hygiene

August 1, 2022 (press release) –

  • Care Solutions business shifts portfolio further to System Solutions
  • Focus on increased investment in high-growth and high-margin, sustainable specialty chemicals
  • Sale includes North plant at Hopewell, Virginia, site

Evonik, one of the world’s leading providers of personal care ingredients, is continuing its portfolio transformation to System Solutions by divesting its U.S. betaine business. On July 28, 2022, Evonik signed an agreement to sell its whole betaines business in Hopewell, Virginia in the U.S. - inclusive staff and part of the site - to specialty chemicals company Kensing LLC. This divestment marks the next stage of the transformation of Evonik’s Care Solutions business line to become a System Solutions provider for the personal care and cleaning industries.

The Care Solutions business line is a cornerstone of Evonik’s growing life sciences division, Nutrition & Care, which aims to increase its share of System Solutions from 20 percent today to more than 50 percent by 2030. This goal supports the transformation of the whole company to make sustainability the central driver of innovation as Next Generation Evonik. System Solutions are multi-component offerings across products, technologies and services that are tailored to a unique customer need and often have proven sustainability benefits.

“Betaines are an attractive and profitable business, but they are no longer core to Care Solutions’ strategy, which is driven by high-value-added System Solutions. We are convinced, with the new ownership under Kensing, the business will be in good hands for the North plant employees of Evonik,” said Yann d'Hervé, head of Evonik’s Care Solutions business line.

Betaines are amphoteric surfactants, which are used as ingredients in the formulation of shampoos, hair conditioners and skin care products for the personal care industry and in a wide
range of other consumer applications. This portfolio adjustment of the Care Solutions business line will enable further investments and acquisitions of sustainable specialties, especially within the innovation growth field cosmetic solutions.

In August 2020, Evonik divested its betaine business in the UK with the sale of the Milton Keynes site. In November 2020, it consolidated its European manufacturing activities to support the transition to specialty technology by closing its site in Granollers, Spain. Evonik will continue its betaine businesses in Europe, Asia and Latin America.
The remaining part of the Hopewell facility, which produces additives for polyurethane foam manufacture, agricultural and industrial applications, together with approximately 100 employees, will continue to be an important part of Evonik’s North America region.

Evonik is one of the world leaders in specialty chemicals. The company is active in more than 100 countries around the world and generated sales of €15 billion and an operating profit (adjusted EBITDA) of €2.38 billion in 2021. Evonik goes far beyond chemistry to create innovative, profitable and sustainable solutions for customers. About 33,000 employees work together for a common purpose: We want to improve life today and tomorrow.

The focus of the business of the Nutrition & Care division is on health and quality of life. It develops differentiated solutions for active pharmaceutical ingredients, medical devices, nutrition for humans and animals, personal care, cosmetics, and household cleaning. In these resilient end markets, the division generated sales of €3.56 billion in 2021 with about 5,300 employees. 

In so far as forecasts or expectations are expressed in this press release or where our statements concern the future, these forecasts, expectations or statements may involve known or unknown risks and uncertainties. Actual results or developments may vary, depending on changes in the operating environment. Neither Evonik Industries AG nor its group companies assume an obligation to update the forecasts, expectations or statements contained in this release.

* All content is copyrighted by Industry Intelligence, or the original respective author or source. You may not recirculate, redistrubte or publish the analysis and presentation included in the service without Industry Intelligence's prior written consent. Please review our terms of use.

See our dashboard in action - schedule an demo
Chelsey Quick
Chelsey Quick
- VP Client Success -

We offer built-to-order tissue & hygiene coverage for our clients. Contact us for a free consultation.

About Us

We deliver market news & information relevant to your business.

We monitor all your market drivers.

We aggregate, curate, filter and map your specific needs.

We deliver the right information to the right person at the right time.

Our Contacts

1990 S Bundy Dr. Suite #380,
Los Angeles, CA 90025

+1 (310) 553 0008

About Cookies On This Site

We collect data, including through use of cookies and similar technology ("cookies") that enchance the online experience. By clicking "I agree", you agree to our cookies, agree to bound by our Terms of Use, and acknowledge our Privacy Policy. For more information on our data practices and how to exercise your privacy rights, please see our Privacy Policy.